{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:43:45Z","timestamp":1793040225835,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["V3-24038"],"award-info":[{"award-number":["V3-24038"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0343"],"award-info":[{"award-number":["P3-0343"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-026-02897-3","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:48:17Z","timestamp":1772704097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study"],"prefix":"10.1186","volume":"25","author":[{"given":"Jan","family":"Kafol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Novakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Cevc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Krevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenart","family":"Kafol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamarija","family":"Kelenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klarisa","family":"Kepic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Vrbinc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Svarc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urh","family":"Groselj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Jug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2897_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and Risks, 1990\u20132022. J Am Coll Cardiol. 2023;82:2350\u2013473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"key":"2897_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38:2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"key":"2897_CR3","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","volume":"378","author":"Heart Protection Study Collaborative G","year":"2011","unstructured":"Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of Lowering LDL cholesterol with Simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet. 2011;378:2013\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(11)61125-2.","journal-title":"Lancet"},{"key":"2897_CR4","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956\u201364. https:\/\/doi.org\/10.1210\/jc.2012-1563.","journal-title":"J Clin Endocrinol Metab"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(94)90566-5","volume":"344","author":"Scandinavian Simvastatin Survival Study G","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study G. Randomised trial of cholesterol Lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet. 1994;344:1383\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(94)90566-5.","journal-title":"Lancet"},{"key":"2897_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"key":"2897_CR7","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","volume":"80","author":"C Writing","year":"2022","unstructured":"Writing C, Lloyd-Jones DM, Morris PB, et al. ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366\u2013418. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.006","journal-title":"J Am Coll Cardiol"},{"key":"2897_CR8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to Statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"},{"key":"2897_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"2897_CR10","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"key":"2897_CR11","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Bytyci","year":"2022","unstructured":"Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of Statin intolerance: a meta-analysis. Eur Heart J. 2022;43:3213\u201323. https:\/\/doi.org\/10.1093\/eurheartj\/ehac015.","journal-title":"Eur Heart J"},{"key":"2897_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015;11:1\u201323. https:\/\/doi.org\/10.5114\/aoms.2015.49807.","journal-title":"Arch Med Sci"},{"key":"2897_CR13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"2897_CR14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"2897_CR15","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"2897_CR16","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1016\/j.jacl.2024.05.003","volume":"18","author":"I Naoum","year":"2024","unstructured":"Naoum I, Saliba W, Aker A, Zafrir B. Lipid-lowering therapy with inclisiran in the real-world setting: initial data from a National health care service. J Clin Lipidol. 2024;18:e809\u201316. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.003.","journal-title":"J Clin Lipidol"},{"key":"2897_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cjco.2022.03.003","volume":"4","author":"M Gupta","year":"2022","unstructured":"Gupta M, Mancini GBJ, Wani RJ, et al. Real-World insights into Evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study. CJC Open. 2022;4:558\u201367. https:\/\/doi.org\/10.1016\/j.cjco.2022.03.003.","journal-title":"CJC Open"},{"key":"2897_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","volume":"17","author":"J Mulder","year":"2023","unstructured":"Mulder J, Galema-Boers AMH, van Roeters JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023;17:818\u201327. https:\/\/doi.org\/10.1016\/j.jacl.2023.09.005.","journal-title":"J Clin Lipidol"},{"key":"2897_CR19","volume-title":"Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998","author":"WHOHG Programme","year":"1999","unstructured":"Programme WHOHG. Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. In. Geneva: World Health Organization; 1999."},{"key":"2897_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf352","author":"J Kafol","year":"2025","unstructured":"Kafol J, Miranda B, Sikonja R, et al. Proposal of a Familial hypercholesterolemia pediatric diagnostic score (FH-PeDS). Eur J Prev Cardiol. 2025. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf352.","journal-title":"Eur J Prev Cardiol"},{"key":"2897_CR21","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/j.gim.2022.06.010","volume":"24","author":"U Sustar","year":"2022","unstructured":"Sustar U, Kordonouri O, Mlinaric M, et al. Universal screening for Familial hypercholesterolemia in 2 populations. Genet Med. 2022;24:2103\u201311. https:\/\/doi.org\/10.1016\/j.gim.2022.06.010.","journal-title":"Genet Med"},{"key":"2897_CR22","doi-asserted-by":"publisher","first-page":"119118","DOI":"10.1016\/j.atherosclerosis.2025.119118","volume":"402","author":"Q Ain","year":"2025","unstructured":"Ain Q, Sikonja J, Sadiq F, et al. Cascade screening of a Pakistani consanguineous Familial hypercholesterolemia cohort: identification of seven new homozygous patients. Atherosclerosis. 2025;402:119118. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119118.","journal-title":"Atherosclerosis"},{"key":"2897_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.gim.2021.09.012","volume":"24","author":"JR Chora","year":"2022","unstructured":"Chora JR, Iacocca MA, Tichy L, et al. The clinical genome resource (ClinGen) Familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24:293\u2013306. https:\/\/doi.org\/10.1016\/j.gim.2021.09.012.","journal-title":"Genet Med"},{"key":"2897_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/gim.2017.151","volume":"20","author":"JR Chora","year":"2018","unstructured":"Chora JR, Medeiros AM, Alves AC, Bourbon M. Analysis of publicly available LDLR, APOB, and PCSK9 variants associated with Familial hypercholesterolemia: application of ACMG guidelines and implications for Familial hypercholesterolemia diagnosis. Genet Med. 2018;20:591\u20138. https:\/\/doi.org\/10.1038\/gim.2017.151.","journal-title":"Genet Med"},{"key":"2897_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00508-023-02245-w","volume":"136","author":"C Ebenbichler","year":"2024","unstructured":"Ebenbichler C, Drexel H, Hanusch U, et al. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wien Klin Wochenschr. 2024;136:77\u201386. https:\/\/doi.org\/10.1007\/s00508-023-02245-w.","journal-title":"Wien Klin Wochenschr"},{"key":"2897_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1080\/03007995.2020.1786678","volume":"36","author":"DR Leitner","year":"2020","unstructured":"Leitner DR, Toplak H, Kedenko L, et al. Efficacy and tolerability of Alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study. Curr Med Res Opin. 2020;36:1419\u201325. https:\/\/doi.org\/10.1080\/03007995.2020.1786678.","journal-title":"Curr Med Res Opin"},{"key":"2897_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","volume":"366","author":"KK Ray","year":"2023","unstructured":"Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with Evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14\u201321. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.01.002.","journal-title":"Atherosclerosis"},{"key":"2897_CR28","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1093\/eurjpc\/zwae170","volume":"31","author":"P Gargiulo","year":"2024","unstructured":"Gargiulo P, Basile C, Galasso G, et al. Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin\/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry. Eur J Prev Cardiol. 2024;31:1806\u201316. https:\/\/doi.org\/10.1093\/eurjpc\/zwae170.","journal-title":"Eur J Prev Cardiol"},{"key":"2897_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","volume":"366","author":"P Gargiulo","year":"2023","unstructured":"Gargiulo P, Basile C, Cesaro A, et al. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT). Atherosclerosis. 2023;366:32\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.01.001.","journal-title":"Atherosclerosis"},{"key":"2897_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","volume":"25","author":"TA Lagace","year":"2014","unstructured":"Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25:387\u201393. https:\/\/doi.org\/10.1097\/MOL.0000000000000114.","journal-title":"Curr Opin Lipidol"},{"key":"2897_CR31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Schatz U, Perakakis N, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112:1639\u201349. https:\/\/doi.org\/10.1007\/s00392-023-02247-8.","journal-title":"Clin Res Cardiol"},{"key":"2897_CR32","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","volume":"85","author":"P Gargiulo","year":"2025","unstructured":"Gargiulo P, Marzano F, Crisci M, et al. Real-World efficacy and safety of inclisiran: A Single-Country, Multicenter, observational study (CHOLINET Registry). J Am Coll Cardiol. 2025;85:536\u201340. https:\/\/doi.org\/10.1016\/j.jacc.2024.10.106.","journal-title":"J Am Coll Cardiol"},{"key":"2897_CR33","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/j.jacl.2024.04.045","volume":"18","author":"L Popadic","year":"2024","unstructured":"Popadic L, Ma X, Ali Y, et al. Treatment patterns among early inclisiran vs Anti\u2013PCSK9 mAbs users: A retrospective analysis of US claims databases. J Clin Lipidol. 2024;18:e515\u20136. https:\/\/doi.org\/10.1016\/j.jacl.2024.04.045.","journal-title":"J Clin Lipidol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-026-02897-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-026-02897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:42:50Z","timestamp":1776076970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12944-026-02897-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1186\/s12944-026-02897-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Slovenian National Medical Ethics Committee (No. 22\/01\/2017; 0120\u2009\u2212\u200914\/2017-2; 0120\u2009\u2212\u200914\/2017-5). The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the dyslipidemia registry.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"J.K. received speaking honoraria from Medison Pharma. Z.F. received speaker honoraria \/ consultancy fees from Novo Nordisk, Swixx Biopharma and Amgen. Z.F. received research funding from Novartis. Z.F. research work was supported by the Slovenian Research and Innovation Agency Program J3-4525. M.N. and B.K. received speaking honoraria from Novartis, Swixx Biopharma, Amgen and Krka. L.S.S. serves as the Chief Medical Officer of the Family Heart Foundation. U.G. received speaking honoraria from Novartis, AstraZeneca and Ultragenyx. U.G. research work was supported by the Slovenian Research and Innovation Agency Program P3-0343. B.J. research work was supported by the Slovenian Research and Innovation Agency Program V3-24038. Other authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}